Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Investor Day (2025)
10 slides from Orion Oyj Class A's investor day presentation, 2025
Slide 1: Generics and Consumer Health
Generics and Consumer Health Satu Ahomäki, Executive Vice President
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Dedicated effort and keen market insights have driven the expansion of the foundational portfolio
Dedicated effort and keen market insights have driven the expansion of the foundational portfolio 557 • Active in-licensing has always been in the core of 518 528 107 36 Orion’s activities 51 +4.7% • Constant flow of new launches in Nordics and Eastern Europe enabled the growth 466 493 450 • Strong
Slide 4: Strategic roadmap to realizing our vision
Strategic roadmap to realizing our vision Focus areas 2024-2025 2026-2029 2030-2035 VISION Growth generation Defend and improve market positions in Nordics and Eastern Europe Profitable business growth Transformation of the portfolio towards complex and value-add generics Portfolio with focused mana
Slide 5: Our core commitments
1 Our core commitments • Accelerate new product flow through Growth in-licensing and development generation • Drive profitability through healthy • Pilot new sales channel in Consumer Health price levels and volume increases • Actively manage the cost base • Efficient internal processes Value-add gr
Slide 6: A value-add hospital generic provide additional benefits beyond the standard generic versions
A value-add hospital generic provide additional benefits beyond the standard generic versions The main objectives of the value-add growth project are to build a portfolio of value-adding hospital generics and create a required commercialization capabilities in the Europe Big 5 countries Portfolio of
Slide 7: Accelerating future growth with D2C pilot – our online store Well by Orion Pharma
Accelerating future growth with D2C pilot – our online store Well by Orion Pharma, launched in Sweden • The pilot project launched in Sweden in May 2025 • Direct-to-Consumer (D2C) online store aims to accelerate Consumer Health growth, featuring expert-curated product bundles for mothers and babies,
Slide 8: Capabilities and competitive edge
Capabilities and competitive edge Leadership in Finland, Expansion in Scandinavia and Poland • Market position in Finland 1st . Total market share 11%. Reference-priced products and self-care market share ~25%. • Market position in Scandinavian generics sector 5th • In Poland, Orion Pharma is recogn
Slide 9: How Generics and Consumer Health is building growth
How Generics and Consumer Health is building growth Growth through innovation Growth through geographic expansion • Transformation of the product • Expanding commercial footprint in portfolio towards complex and Europe Big5 countries value-adding generics • New sales channels Growth through portfoli
Slide 10: Q&A
GRION PHARMA Q&A